Evidence map›Paper›PMID 32675286›Full record

ArticleThe Journal of biological chemistry2020

Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.

Soichiro S Ito, Yosuke Nakagawa, Masaya Matsubayashi, Yoshihiko M Sakaguchi, Shinko Kobashigawa, Takeshi K Matsui, Hitoki Nanaura, Mari Nakanishi, Fumika Kitayoshi, Sotaro Kikuchi and 8 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Soichiro S ItoDepartment of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Nara, Japan.
Yosuke NakagawaDepartment of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Nara, Japan.
Masaya MatsubayashiDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
Yoshihiko M SakaguchiDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
Shinko KobashigawaDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
Takeshi K MatsuiDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan; Department of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Hitoki NanauraDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan; Department of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Mari NakanishiDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
Fumika KitayoshiDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
Sotaro KikuchiDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan.
Atsuhisa KajiharaDepartment of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Nara, Japan.
Shigehiro TamakiDepartment of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Nara, Japan.
Kazuma SugieDepartment of Neurology, Nara Medical University, Kashihara, Nara, Japan.
Genro KashinoRadioisotope Research Center, Nara Medical University, Kashihara, Nara, Japan.
Akihisa TakahashiGunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
Masatoshi HasegawaDepartment of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan.
Eiichiro MoriDepartment of Future Basic Medicine, Nara Medical University, Kashihara, Nara, Japan. Electronic address: emori@naramed-u.ac.jp.
Tadaaki KiritaDepartment of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Nara, Japan. Electronic address: tkirita@naramed-u.ac.jp.
Nara Medical University · JPGunma University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anticancer agent 5-fluorouracil (5-FU) is cytotoxic and often used to treat various cancers. 5-FU is thought to inhibit the enzyme thymidylate synthase, which plays a role in nucleotide synthesis and has been found to induce single- and double-strand DNA breaks. ATR Ser/Thr kinase (ATR) is a principal kinase in the DNA damage response and is activated in response to UV- and chemotherapeutic drug-induced DNA replication stress, but its role in cellular responses to 5-FU is unclear. In this study, we examined the effect of ATR inhibition on 5-FU sensitivity of mammalian cells. Using immunoblotting, we found that 5-FU treatment dose-dependently induced the phosphorylation of ATR at the autophosphorylation site Thr-1989 and thereby activated its kinase. Administration of 5-FU with a specific ATR inhibitor remarkably decreased cell survival, compared with 5-FU treatment combined with other major DNA repair kinase inhibitors. Of note, the ATR inhibition enhanced induction of DNA double-strand breaks and apoptosis in 5-FU-treated cells. Using gene expression analysis, we found that 5-FU induced the activation of the intra-S cell-cycle checkpoint. Cells lacking

Indexed as

Ataxia Telangiectasia Mutated ProteinsCell Line, TumorDNA End-Joining RepairDrug Resistance, NeoplasmFluorouracilHumansNeoplasm ProteinsNeoplasmsProtein Kinase InhibitorsRecombinational DNA RepairUltraviolet RaysAtaxia Telangiectasia Mutated ProteinsATR protein, humanFluorouracilNeoplasm ProteinsProtein Kinase Inhibitors5-fluorouracilanticancer drugantineoplastic agentapoptosisATR serine/threonine kinaseBRCA2cancercell cyclecell-cycle checkpointchemotherapyDNA damage responseDNA double-strand breaksDNA repairhomologous recombination

Identifiers

PMID32675286
PMCPMC7489910
OpenAlexW3042436554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.